Already in the 1990s, there appeared the very first reports about the potential use of highly specific ligands that are inhibitors of prostate receptor-specific membrane antigen (PSMA) in the diagnosis and therapy of PC [11,12,13]. The gene discussed is FOLH1; the disease is pachyonychia congenita.